Format

Send to

Choose Destination
Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834.

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Author information

1
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. emayer@partners.org

Abstract

Src, a membrane-associated nonreceptor tyrosine kinase, plays a crucial role in the coordination and facilitation of cell-signaling pathways controlling a wide range of cellular functions, including growth, survival, invasion, adhesion, and migration. Deregulation and increased activity of Src has been observed in multiple human malignancies, prompting the development of specific inhibitors of Src. In preclinical studies, Src inhibitors show antitumor effects in multiple solid tumor types. Recently completed early-phase trials using the inhibitors dasatinib and bosutinib have suggested modest activity as monotherapy in breast and prostate cancer, with potentially greater activity in combination regimens. Given the interaction between Src and the estrogen receptor, ongoing trials are exploring combinations with endocrine therapy. The relationship between Src and the vascular endothelial growth factor receptor also justifies investigation of combinations with angiogenesis inhibitors. Future trials will continue to explore the contribution of Src inhibition with both chemotherapy and targeted agents.

PMID:
20634194
DOI:
10.1158/1078-0432.CCR-09-1834
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center